(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
07 July 2022 (07.07.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/143844 A1

(51) International Patent Classification:
A61K 31/5025 (2006.01) *A61K 9/10* (2006.01)
A61K 31/503 (2006.01) *C07D 471/04* (2006.01)
A61K 9/14 (2006.01) *A61P 31/16* (2006.01)

(21) International Application Number:
PCT/CN2021/142759

(22) International Filing Date:
30 December 2021 (30.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/131,886 30 December 2020 (30.12.2020) US

(71) Applicants: **TAIGEN BIOTECHNOLOGY CO., LTD.** [CN/CN]; 7F., No.138 Xinming Rd., Neihu Dist., Taipei, Taiwan (CN). **TAIGEN BIOPHARMACEUTICALS CO. (BEIJING) , LTD.** [CN/CN]; Suite 2312, A Tower, Full Link Building, No. 18, Chaoyangmenwaidajie, Chaoyang Dist., Beijing 100020 (CN).

(72) Inventors: **YEN, Chi-Feng**; 6F., No.149, Sec.6, Nanjing E. Rd., Neihu Dist., Taipei, Taiwan (CN). **TIEN, Fang-Wei**; 8F., No.8-7, Ln.132, Jingxin St., Zhonghe Dist., New Taipei City, Taiwan (CN).

(74) Agent: **GE CHENG & CO., LTD**; CHENG, David W., Level 19, Tower E3, The Towers, Oriental Plaza, No.1 East Chang An Avenue, Dongcheng District, Beijing 100738 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: AMORPHOUS SOLID DISPERSION FORMULATION

(57) Abstract: Provided is an amorphous solid dispersion containing a Cap-dependent endonuclease inhibitor or a pharmaceutically acceptable salt thereof for oral administration, wherein the Cap-dependent endonuclease inhibitor or a pharmaceutically acceptable salt thereof is dispersed in a matrix formed from the pharmaceutically acceptable polymer. Further disclosed are methods for preparing a above amorphous solid dispersion and a use thereof for treating virus infection and a pharmaceutical composition containing same.

WO 2022/143844 A1